These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 30254423)

  • 1. GlycoPEGylated recombinant factor IX for hemophilia B in context.
    Santagostino E; Mancuso ME
    Drug Des Devel Ther; 2018; 12():2933-2943. PubMed ID: 30254423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonacog beta pegol in previously treated children with hemophilia B: results from an international open-label phase 3 trial.
    Carcao M; Zak M; Abdul Karim F; Hanabusa H; Kearney S; Lu MY; Persson P; Rangarajan S; Santagostino E
    J Thromb Haemost; 2016 Aug; 14(8):1521-9. PubMed ID: 27174727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant long-acting glycoPEGylated factor IX (nonacog beta pegol) in haemophilia B: assessment of target joints in multinational phase 3 clinical trials.
    Negrier C; Young G; Abdul Karim F; Collins PW; Hanabusa H; Colberg T; Goldman B; Walsh CE;
    Haemophilia; 2016 Jul; 22(4):507-13. PubMed ID: 26936227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonacog Beta Pegol: A Review in Haemophilia B.
    Syed YY
    Drugs; 2017 Dec; 77(18):2003-2012. PubMed ID: 29124682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-factor consumption for major surgery in haemophilia B with long-acting recombinant glycoPEGylated factor IX.
    Escobar MA; Tehranchi R; Karim FA; Caliskan U; Chowdary P; Colberg T; Giangrande P; Giermasz A; Mancuso ME; Serban M; Tsay W; Mahlangu JN
    Haemophilia; 2017 Jan; 23(1):67-76. PubMed ID: 27480487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of a novel extended half-life glycoPEGylated factor IX, nonacog beta pegol (N9-GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials.
    Tiede A; Abdul-Karim F; Carcao M; Persson P; Clausen WHO; Kearney S; Matsushita T; Negrier C; Oldenburg J; Santagostino E; Young G
    Haemophilia; 2017 Jul; 23(4):547-555. PubMed ID: 28233381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonacog beta pegol (N9-GP) in haemophilia B: A multinational phase III safety and efficacy extension trial (paradigm™4).
    Young G; Collins PW; Colberg T; Chuansumrit A; Hanabusa H; Lentz SR; Mahlangu J; Mauser-Bunschoten EP; Négrier C; Oldenburg J; Patiroglu T; Santagostino E; Tehranchi R; Zak M; Karim FA
    Thromb Res; 2016 May; 141():69-76. PubMed ID: 26970716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement in health-related quality of life in patients with haemophilia B treated with nonacog beta pegol, a new extended half-life recombinant FIX product.
    Chowdary P; Kearney S; Regnault A; Hoxer CS; Yee DL
    Haemophilia; 2016 Jul; 22(4):e267-74. PubMed ID: 27352908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once-weekly prophylaxis with 40 IU/kg nonacog beta pegol (N9-GP) achieves trough levels of >15% in patients with haemophilia B: Pooled data from the paradigm™ trials.
    Oldenburg J; Carcao M; Lentz SR; Mahlangu J; Mancuso ME; Matsushita T; Négrier C; Clausen WHO; Ehrenforth S; Young G
    Haemophilia; 2018 Nov; 24(6):911-920. PubMed ID: 30248217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX.
    Collins PW; Møss J; Knobe K; Groth A; Colberg T; Watson E
    J Thromb Haemost; 2012 Nov; 10(11):2305-12. PubMed ID: 22998153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measuring factor IX activity of nonacog beta pegol with commercially available one-stage clotting and chromogenic assay kits: a two-center study.
    Bowyer AE; Hillarp A; Ezban M; Persson P; Kitchen S
    J Thromb Haemost; 2016 Jul; 14(7):1428-35. PubMed ID: 27107268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new modeling approach allowing prediction and comparison of the long-term outcomes of treatments for hemophilia B.
    Keep MV; Hoxer CS; Hemstock M; Groth AV; Knight C
    J Comp Eff Res; 2018 Jan; 7(1):39-48. PubMed ID: 28556675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial.
    Collins PW; Young G; Knobe K; Karim FA; Angchaisuksiri P; Banner C; Gürsel T; Mahlangu J; Matsushita T; Mauser-Bunschoten EP; Oldenburg J; Walsh CE; Negrier C;
    Blood; 2014 Dec; 124(26):3880-6. PubMed ID: 25261199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Safety and Efficacy of Nonacog Beta Pegol (N9-GP) Administered for at Least 5 Years in Previously Treated Children with Hemophilia B.
    Carcao M; Kearney S; Lu MY; Taki M; Rubens D; Shen C; Santagostino E
    Thromb Haemost; 2020 May; 120(5):737-746. PubMed ID: 32369845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FIXing postinfusion monitoring: Assay experiences with N9-GP (nonacog beta pegol; Refixia
    Ezban M; Hermit MB; Persson E
    Haemophilia; 2019 Jan; 25(1):154-161. PubMed ID: 30664825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics, Efficacy, and Safety of Nonacog Alfa in Previously Treated Patients with Moderately Severe to Severe Hemophilia B.
    Korth-Bradley JM; Rendo P; Smith L; Altisent C
    Clin Ther; 2016 Apr; 38(4):936-44. PubMed ID: 26969334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overestimation of N-glycoPEGylated factor IX activity in a one-stage factor IX clotting assay owing to silica-mediated premature conversion to activated factor IX.
    Rosén P; Rosén S; Ezban M; Persson E
    J Thromb Haemost; 2016 Jul; 14(7):1420-7. PubMed ID: 27169618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates.
    Preijers T; Bukkems L; van Spengler M; Leebeek F; Cnossen M; Mathôt R
    Eur J Clin Pharmacol; 2021 Aug; 77(8):1193-1200. PubMed ID: 33624121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insight into health-related quality of life of young children with haemophilia B treated with long-acting nonacog beta pegol recombinant factor IX.
    Carcao M; Kearney S; Santagostino E; Oyesiku JOO; Young NL; Meunier J; Hoxer CS; Zhang C; Blanchette VS
    Haemophilia; 2017 May; 23(3):e222-e224. PubMed ID: 28371032
    [No Abstract]   [Full Text] [Related]  

  • 20. Trenonacog alfa for prophylaxis, on-demand and perioperative management of hemophilia B.
    Brennan Y; Curnow J; Favaloro EJ
    Expert Opin Biol Ther; 2018 Jan; 18(1):95-100. PubMed ID: 29172774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.